Tesofensine (NS2330): A Research Review of the Triple Monoamine Reuptake Inhibitor

Tesofensine (NS2330) is a synthetic triple monoamine reuptake inhibitor that has become one of the most studied investigational metabolic compounds in the preclinical peptide and small-molecule research space. Originally characterized in neurodegenerative disease models before being redirected toward energy-balance research, it occupies a distinctive niche because it acts simultaneously on three transporter systems rather than a single receptor. This review summarizes the reported pharmacology, mechanism of action, and experimental literature. All content is provided strictly for research reference.

By Peptide Insider Research Team · 11 min read · Last updated September 3, 2026

On this page

• Introduction
• Biological background: the monoamine transporter system
• Structure and mechanism of action
• Evidence by research domain
• Tesofensine vs. other metabolic research compounds
• Limitations and research considerations
• Where to source for research
• Frequently asked research questions
• Works cited

Introduction

Tesofensine is a synthetic compound that was first developed under the code NS2330 as a candidate for neurodegenerative disease research, where investigators studied its ability to enhance monoaminergic neurotransmission in models of Alzheimer's and Parkinson's disease [1,6]. Early clinical programs in those indications reported only limited efficacy on cognitive and motor endpoints, and development for neurodegeneration was discontinued [6]. During that work, researchers incidentally observed changes in body weight, which redirected the compound toward metabolic and energy-balance research [2,6].

Unlike the peptide secretagogues and receptor agonists reviewed elsewhere on Peptide Insider, tesofensine is a low-molecular-weight organic molecule rather than a peptide. It is grouped with metabolic research compounds because its most extensively documented experimental effects concern feeding behavior, monoamine signaling, and energy expenditure — the same physiological axes studied for compounds such as AOD-9604 and 5-Amino-1MQ. This review treats tesofensine strictly as a laboratory reference compound.

Biological background: the monoamine transporter system

Dopamine, norepinephrine, and serotonin are monoamine neurotransmitters that regulate reward, arousal, mood, and appetitive behavior. After release into the synaptic cleft, their signaling is terminated by presynaptic reuptake through three transporter proteins: the dopamine transporter (DAT), the norepinephrine transporter (NET), and the serotonin transporter (SERT) [1,4]. By clearing neurotransmitter from the synapse, these transporters set the duration and intensity of monoaminergic signaling.

Research on energy balance has repeatedly implicated central dopamine tone in the regulation of food intake. Diet-induced obese (DIO) rodent models have been reported to show reduced extracellular dopamine in the nucleus accumbens and prefrontal cortex, a state hypothesized to drive compensatory feeding [3]. This framework — that blunted monoamine signaling accompanies dysregulated energy balance — provides the rationale for studying reuptake inhibition as a lever on feeding behavior in experimental settings.

Structure and mechanism of action

Tesofensine is a small-molecule triple monoamine reuptake inhibitor, sometimes abbreviated SNDRI (serotonin–norepinephrine–dopamine reuptake inhibitor) or TRI (triple reuptake inhibitor). It binds and inhibits DAT, NET, and SERT, increasing the synaptic availability of all three neurotransmitters simultaneously [1,4,6]. This multi-transporter profile distinguishes it from selective agents that act on a single monoamine system.

Receptor-level dependence. Mechanistic work in DIO rat models has clarified which downstream receptors mediate the observed reduction in food intake. Co-administration of selective antagonists reported that blocking alpha-1 adrenoceptors or dopamine D1 receptors reversed tesofensine-associated hypophagia, whereas blocking D2, D3, or 5-HT2A/2C receptors did not [1]. This suggests the anorexigenic signal observed in these models is driven indirectly through alpha-1 and D1 pathways rather than through serotonergic receptors.

Hypothalamic circuitry. More recent electrophysiological and chemogenetic research reported that tesofensine inhibits a subset of GABAergic neurons in the lateral hypothalamus — a population that normally promotes feeding. Chemogenetic silencing of those same neurons enhanced the food-suppressing effect observed with tesofensine, and the compound was associated with blunted body-weight rebound in these models [7]. Behavioral testing in that work indicated the effect was not attributable to taste aversion or altered sucrose palatability [7].

Pharmacokinetics. Tesofensine is characterized in the literature by a notably long elimination half-life of approximately 220 hours (roughly nine days), metabolism primarily via hepatic CYP3A4 to an active metabolite designated M1 (NS2360), and partial renal excretion [6]. The long half-life is a defining pharmacokinetic feature frequently cited in research discussions of the compound.

Evidence by research domain

The published literature on tesofensine spans preclinical neuroscience, preclinical metabolic models, and human clinical investigation. The table summarizes the principal research domains.

Preclinical monoamine and feeding research

Rodent studies form the mechanistic backbone of the tesofensine literature. Work in DIO models reported that the compound normalized reduced forebrain dopamine levels and reduced food intake, with pharmacological dissection pointing to alpha-1 adrenoceptor and dopamine D1 receptor involvement [1,3]. Circuit-level research in the lateral hypothalamus added resolution by identifying a specific GABAergic neuronal population modulated by the compound [7].

Energy-expenditure research

Several reports investigated whether observed weight changes in models reflected reduced intake alone or an additional metabolic component. Human calorimetry work reported increased energy expenditure during the night and enhanced 24-hour fat oxidation, and rodent pair-feeding experiments suggested a thermogenic contribution [4,5]. These findings are described as emerging rather than definitive.

Clinical investigation

The most cited clinical dataset is the Phase 2 TIPO-1 randomized, double-blind, placebo-controlled trial, which studied graded oral doses in adults with obesity alongside an energy-restricted diet [2]. The trial reported dose-related reductions in body weight, body fat, and waist circumference, and documented a dose-dependent increase in heart rate as its principal safety signal [2]. Development for general obesity did not proceed to approval; subsequent programs explored a fixed-dose combination with a beta-blocker (metoprolol) intended to attenuate the heart-rate signal, studied in rare metabolic conditions [2]. Tesofensine remains investigational and unapproved for general use.

Tesofensine vs. other metabolic research compounds

Because tesofensine is often discussed alongside peptide metabolic agents, the comparison below frames its research profile relative to compounds reviewed elsewhere on this site. This is a mechanistic comparison for research context only.

Limitations and research considerations

Model dependence. The majority of mechanistic findings derive from rodent DIO models, and translation of receptor-dependence data to other systems remains uncertain [1,3,7].

Cardiovascular signal. The dose-dependent heart-rate increase reported in clinical research is a recurring theme in the literature and a central reason the compound did not advance to approval for general obesity [2].

Long half-life. The ~220-hour half-life complicates experimental design, washout, and interpretation of repeated-exposure studies [6].

Investigational status. Tesofensine is not an approved therapeutic in most jurisdictions. Nothing in this review should be interpreted as guidance for human or veterinary use, and no dosing information is provided.

Where to source for research

Reference-grade material handling and documentation matter when designing reproducible experiments. Laboratories evaluating investigational compounds for in vitro or preclinical work typically compare suppliers on certificate-of-analysis transparency, third-party analytical testing, and lot traceability. Among suppliers in the research space, Short Chain Aminos publishes analytical documentation for its research catalog, while BioPep, Catalyst Research, and Apex Research Services similarly position their materials for laboratory research use. Researchers should independently verify purity data and confirm that any material is designated strictly for research use. For a structured framework, see our guide to evaluating research peptide suppliers.

Frequently asked research questions

What class of compound is tesofensine?

Tesofensine is a small-molecule triple monoamine reuptake inhibitor (SNDRI). In research it is documented to inhibit the dopamine, norepinephrine, and serotonin transporters simultaneously, increasing synaptic availability of all three neurotransmitters [1,6]. It is not a peptide.

How does tesofensine differ from selective reuptake inhibitors?

Selective inhibitors act on one transporter, whereas tesofensine inhibits DAT, NET, and SERT together [1,4]. Preclinical research indicates its feeding-related effects depend indirectly on alpha-1 adrenoceptor and dopamine D1 receptor signaling rather than on serotonergic receptors [1].

Why was tesofensine originally developed?

It was first studied as NS2330 for neurodegenerative disease research, including Alzheimer's and Parkinson's models. Those programs reported limited efficacy and were discontinued, after which incidental weight changes redirected research toward metabolic and energy-balance studies [2,6].

What did clinical trials report?

The Phase 2 TIPO-1 trial reported dose-related reductions in body weight, body fat, and waist circumference in adults with obesity, alongside a dose-dependent increase in heart rate that became a central safety consideration [2]. The compound remains investigational and unapproved for general obesity.

What is notable about its pharmacokinetics?

Tesofensine has an unusually long elimination half-life of approximately 220 hours (about nine days). It is metabolized primarily by hepatic CYP3A4 to an active metabolite, M1 (NS2360), with partial renal excretion [6].

Is tesofensine approved for any use?

No. Tesofensine is an investigational compound and is not approved as a therapeutic in most jurisdictions. All information here is for research reference only and is not intended for human or veterinary use.

Works cited

1. Axel AMD, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010;35(7):1464-1476. PMID: 20200509.
2. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. PMID: 18950853.
3. Hansen HH, et al. Tesofensine effects on forebrain dopamine in diet-induced obese rats. PLoS One. 2013. PMID: 23932919.
4. Sjödin A, Gasteyger C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes. 2010;34(11):1634-1643. PMID: 20479765.
5. Hansen HH, Jensen MM, Overgaard A, et al. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels. Physiol Behav. 2010. PMID: 20385125.
6. NS-2330 (tesofensine) pharmacology and pharmacokinetics review. Curr Opin Investig Drugs. PMC2000606.
7. Perez CI, Luis-Islas J, Lopez A, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS One. 2024;19(4):e0300544.